Lenalidomide for bortezomib-resistant multiple myeloma.
Briani
Chiara
C
Berno
Tamara
T
Campagnolo
Marta
M
Zambello
Renato
R
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D019008:Drug Resistance, Neoplasm; D006305:Health Status Indicators; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide
Nat Rev Clin Oncol. 2010 May;7(5):289-94
20351701
Cancer. 2007 Sep 1;110(5):1042-9
17654660
J Peripher Nerv Syst. 2007 Sep;12(3):210-5
17868248
Neurology. 2009 Sep 8;73(10):812-3
19738177
Expert Opin Pharmacother. 2009 Jan;10(1):125-33
19236186
Neurology. 2004 Jun 22;62(12):2288-90
15210897